Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2012

View Archived Issues

New PAK-4 inhibitor under development to treat gastric cancers

Scientists discover novel neurotrophic drug to treat cognitive decline

Findings presented from two phase III trials of Lu-AA-21004 in GAD

Kinetin shows promise to treat familial dysautonomia

Astellas Pharma presents new drug for treatment of transplant rejection

Toray divulges new inhibitors of 11-beta-HSD1

New camptothecin derivatives designed in Spain

IntraCellular Therapies claims novel phosphodiesterase 1B inhibitors

Novel phosphodiesterase inhibitors disclosed

New monoglyceride lipase inhibitors prepared by Sanofi

Syndax Pharmaceuticals designs new azacitidine prodrugs

Roche presents novel drugs for Parkinson's disease

FDA advisory committee to review Xgeva sBLA

Apricus Biosciences finalizes acquisition

BG Medicine files application for second cardiovascular diagnostic test

Marshall Edwards raises funds to advance lead oncology candidates

Opko Health completes acquisition

Symmetry Medical acquires surgical instruments business

Amgen moves AMG-172 to clinic

MethylGene recruiting participants in phase II MGCD-290 study

Gene therapy for wet AMD enters phase I/II testing

Clinical trial application submitted in Russia for AT-001

Clinical development ZP-1846 advances

FDA expands indication of Prevnar 13

Prima BioMed provides update on preclinical testing of Cripto-1 immunotherapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...